Log in

OTCMKTS:REPR - Repro-Med Systems Stock Price, Forecast & News

+0.06 (+1.01 %)
(As of 02/16/2020 02:14 PM ET)
Today's Range
Now: $6.03
50-Day Range
MA: $5.96
52-Week Range
Now: $6.03
Volume165,043 shs
Average Volume36,047 shs
Market Capitalization$240.52 million
P/E RatioN/A
Dividend YieldN/A
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:REPR



Sales & Book Value

Annual Sales$17.35 million
Cash Flow$0.05 per share
Book Value$0.23 per share


Net Income$910,000.00


Market Cap$240.52 million
Next Earnings DateN/A
OptionableNot Optionable

Receive REPR News and Ratings via Email

Sign-up to receive the latest news and ratings for REPR and its competitors with MarketBeat's FREE daily newsletter.

Repro-Med Systems (OTCMKTS:REPR) Frequently Asked Questions

What is Repro-Med Systems' stock symbol?

Repro-Med Systems trades on the OTCMKTS under the ticker symbol "REPR."

How were Repro-Med Systems' earnings last quarter?

Repro-Med Systems, Inc. (OTCMKTS:REPR) issued its quarterly earnings results on Tuesday, August, 6th. The company reported $0.00 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.02. The company earned $5.35 million during the quarter. Repro-Med Systems had a net margin of 0.17% and a return on equity of 7.63%. View Repro-Med Systems' Earnings History.

What is the consensus analysts' recommendation for Repro-Med Systems?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repro-Med Systems in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repro-Med Systems.

Has Repro-Med Systems been receiving favorable news coverage?

Media stories about REPR stock have been trending neutral this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Repro-Med Systems earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Repro-Med Systems.

Who are some of Repro-Med Systems' key competitors?

What other stocks do shareholders of Repro-Med Systems own?

Who are Repro-Med Systems' key executives?

Repro-Med Systems' management team includes the folowing people:
  • Mr. Daniel S. Goldberger, Exec. Chairman (Age 60)
  • Mr. Donald B. Pettigrew, CEO, Pres & Chief Commercial Officer (Age 51)
  • Ms. Karen Fisher, CFO, Treasurer & Corp. Sec. (Age 53)
  • Mr. Manuel A. Marques, Chief Operating Officer (Age 46)
  • Mr. Steven Kamphausen, Global VP of Sales & Marketing

Who are Repro-Med Systems' major shareholders?

Repro-Med Systems' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Parkman Healthcare Partners LLC (1.33%), EAM Investors LLC (0.48%), Essex Investment Management Co. LLC (0.47%), Perceptive Advisors LLC (0.19%), Cavalier Investments LLC (0.09%) and Navellier & Associates Inc (0.09%). Company insiders that own Repro-Med Systems stock include Arthur J Radin, James M Beck and Joseph M Jr Manko. View Institutional Ownership Trends for Repro-Med Systems.

Which major investors are buying Repro-Med Systems stock?

REPR stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, EAM Investors LLC, Essex Investment Management Co. LLC, Perceptive Advisors LLC, Navellier & Associates Inc, Cavalier Investments LLC, Ingalls & Snyder LLC and Perkins Capital Management Inc.. Company insiders that have bought Repro-Med Systems stock in the last two years include Arthur J Radin, James M Beck and Joseph M Jr Manko. View Insider Buying and Selling for Repro-Med Systems.

How do I buy shares of Repro-Med Systems?

Shares of REPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Repro-Med Systems' stock price today?

One share of REPR stock can currently be purchased for approximately $6.03.

How big of a company is Repro-Med Systems?

Repro-Med Systems has a market capitalization of $240.52 million and generates $17.35 million in revenue each year. Repro-Med Systems employs 75 workers across the globe.View Additional Information About Repro-Med Systems.

What is Repro-Med Systems' official website?

The official website for Repro-Med Systems is http://www.rmsmedicalproducts.com/.

How can I contact Repro-Med Systems?

Repro-Med Systems' mailing address is 24 CARPENTER RD, CHESTER NY, 10918. The company can be reached via phone at 845-469-2042 or via email at [email protected]

MarketBeat Community Rating for Repro-Med Systems (OTCMKTS REPR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  81 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about Repro-Med Systems and other stocks. Vote "Outperform" if you believe REPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel